News of the Day

Australians with often debilitating skin conditions collectively known as ‘inflammatory skin diseases’ have an innovative and highly anticipated new treatment within their reach.

Bristol Myers Squibb (BMS) Australia has received Silver Tier Employer status at the Australian Workplace Equality Index's Australian LGBTQ+ Inclusion Awards.

A new report from Sandoz recommends reforms it says could save the PBS up to $75 million per biosimilar molecule, while significantly expanding patient access and reducing healthcare costs.

The TGA has approved the expanded use of Lilly's MOUNJARO (tirzepatide) to include moderate-to-severe obstructive sleep apnoea in adults with obesity.

Australia's use of HTA reflects a prevailing scepticism about the patient experience and a certain belief in the validity of contested economic models. This reflects the current legal framework for decision-making, and it needs to change.

Six months after its launch and close to the time it is due to deliver its final report, the health department has confirmed that the Review of National Blood Arrangements is considering the continued funding of individual products and that the HTA Review will have an impact.

The experience of acute pain has been revealed following the release of the ‘Australian Acute Pain Survey’.

CEO Dr Leearne Hinch said, “Our EXO-OC test addresses a critical unmet need for early detection of ovarian cancer. INOVIQ is now positioned as a global leader in exosome technology, offering best-in-class exosome isolation and diagnostic solutions that can transform precision oncology."

AusBiotech CEO Rebekah Cassidy said, “We believe that strong collaboration across all sides of politics is key to supporting a sustainable, competitive life sciences sector. We welcome the opportunity to continue sharing insights from across the sector with the Shadow Ministry as part of our policy work.”

Radiopharm Theranostics (ASX:RAD) has announced that preclinical data from studies with the Lu177-B7H3-monoclonal antibody RV01 demonstrated favourable biodistribution and showed that RV01 maintained high tumour uptake.

Neurotech International (ASX:NTI) has announced positive results from its first-in-human pharmacokinetic study evaluating NTI164, a proprietary CBDA-rich, standardised formulation of cannabinoids.

Cardiex (ASX:CDX) has announced that the Therapeutic Goods Administration has approved its CONNEQT Pulse arterial health monitor for use in Australia.